Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II
by
Wessells H, Levine N, Hadley ME, Dorr R, Hruby V
Section of Urology,
The University of Arizona College of Medicine,
Tucson, 85724, USA.
hwessels@u.arizona.edu
MA, USA.
Int J Impot Res 2000 Oct; 12 Suppl 4:S74-9

ABSTRACT

We review our experience with Melanotan II, a non-selective melanocortin receptor agonist, in human subjects with erectile dysfunction (ED). Melanotan II was administered to 20 men with psychogenic and organic ED using a double-blind placebo-controlled crossover design. Penile rigidity was monitored for 6 h using RigiScan. Level of sexual desire and side effects were reported with a questionnaire. In the absence of sexual stimulation, Melanotan II led to penile erection in 17 of 20 men. Subjects experienced a mean of 41 min Rigiscan tip rigidity>80%. Increased sexual desire was reported after 13/19 (68%) doses of Melanotan II vs 4/21 (19%) of placebo (P<0.01). Nausea and yawning were frequently reported side effects due to Melanotan II; at a dose of 0.025 mg/kg, 12.9% of subjects had severe nausea. We conclude that Melanotan II is a potent initiator of penile erection in men with erectile dysfunction. Our findings warrant further investigation of melanocortin agonists and antagonists on penile erection

Viagra
PT-141
Melanotan
Yohimbine
Amineptine
Apomorphine
Phentolamine
SSRIs and sex
The menopause
Female sexuality
The Coolidge Effect
Testosterone and sex
Designer aphrodisiacs
Drugs for impotent rabbits
Sexual heath: sildenafil (Viagra)
The pharmacology of penile erection

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family